# Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/FLGT/fulgent-announces-rapid-oral-full-abstract-publication-for-fid-007-within-the-head-and-neck-cancer-track-session-at-the-asco-2026-annual-meeting
Ticker: FLGT
Company: Fulgent Genetics, Inc.
Source: Fulgent Genetics, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.fulgentgenetics.com
## Summary

EL MONTE, Calif. --(BUSINESS WIRE)--May 21, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on

## Article Body
EL MONTE, Calif. --(BUSINESS WIRE)--May 21, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on
## Recent Company News
- 2026-06-25 13:46 EST — [Fulgent Presents Updated FID-007 Data at ASCO 2026](https://biopharmsignal.com/news/FLGT/fulgent-presents-updated-fid-007-data-at-asco-2026) — Source: Fulgent Genetics, Inc.
- 2026-06-25 13:46 EST — [Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/FLGT/fulgent-announces-rapid-oral-full-abstract-publication-for-fid-007-within-the-head-and-neck-cancer-track-session-at-the-asco-2026-annual-meeting) — Source: Fulgent Genetics, Inc.
- 2026-06-25 13:46 EST — [Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference](https://biopharmsignal.com/news/FLGT/fulgent-shares-preliminary-data-from-poster-presentation-at-esmo-2025-conference) — Source: Fulgent Genetics, Inc.
- 2026-06-25 13:46 EST — [Fulgent Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/FLGT/fulgent-reports-third-quarter-2025-financial-results) — Source: Fulgent Genetics, Inc.
- 2026-06-25 13:46 EST — [Fulgent to Participate in Upcoming Conferences](https://biopharmsignal.com/news/FLGT/fulgent-to-participate-in-upcoming-conferences) — Source: Fulgent Genetics, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)